Immunic, Inc. (IMUX) Operating cash flow 2016–2025
Immunic, Inc. (IMUX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$85.8MFY2025 · since FY2016: -$35.8M → -$85.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$85.8M | -1.2% |
| FY2024 | -$84.8M | -19.7% |
| FY2023 | -$70.8M | -8.7% |
| FY2022 | -$65.1M | +21.7% |
| FY2021 | -$83.2M | -80.5% |
| FY2020 | -$46.1M | -61.6% |
| FY2019 | -$28.5M | -193.1% |
| FY2018 | -$9.7M | +75.9% |
| FY2017 | -$40.4M | -12.9% |
| FY2016 | -$35.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMUX financial trends
IMUX RevenueIMUX Net incomeIMUX Net marginIMUX Gross profitIMUX Gross marginIMUX Operating incomeIMUX Operating marginIMUX Free cash flowIMUX Capital expendituresIMUX Return on equityIMUX Stock buybacksIMUX Dividends paidIMUX Total assetsIMUX Total liabilitiesIMUX Shareholders’ equityIMUX overview →